233 related articles for article (PubMed ID: 25635861)
1. Therapy with plasma purified alpha1-antitrypsin (Prolastin®) induces time-dependent changes in plasma levels of MMP-9 and MPO.
Koepke J; Dresel M; Schmid S; Greulich T; Beutel B; Schmeck B; Vogelmeier CF; Janciauskiene S; Koczulla AR
PLoS One; 2015; 10(1):e0117497. PubMed ID: 25635861
[TBL] [Abstract][Full Text] [Related]
2. The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency.
Schmid ST; Koepke J; Dresel M; Hattesohl A; Frenzel E; Perez J; Lomas DA; Miranda E; Greulich T; Noeske S; Wencker M; Teschler H; Vogelmeier C; Janciauskiene S; Koczulla AR
Int J Chron Obstruct Pulmon Dis; 2012; 7():687-96. PubMed ID: 23055718
[TBL] [Abstract][Full Text] [Related]
3. The fibrinogen cleavage product Aα-Val360, a specific marker of neutrophil elastase activity in vivo.
Carter RI; Mumford RA; Treonze KM; Finke PE; Davies P; Si Q; Humes JL; Dirksen A; Piitulainen E; Ahmad A; Stockley RA
Thorax; 2011 Aug; 66(8):686-91. PubMed ID: 21617168
[TBL] [Abstract][Full Text] [Related]
4. SPARTA clinical trial design: exploring the efficacy and safety of two dose regimens of alpha1-proteinase inhibitor augmentation therapy in alpha1-antitrypsin deficiency.
Sorrells S; Camprubi S; Griffin R; Chen J; Ayguasanosa J
Respir Med; 2015 Apr; 109(4):490-9. PubMed ID: 25727857
[TBL] [Abstract][Full Text] [Related]
5. Exogenous alpha 1-antitrypsin down-regulates SERPINA1 expression.
Karadagi A; Johansson H; Zemack H; Salipalli S; Mörk LM; Kannisto K; Jorns C; Gramignoli R; Strom S; Stokkeland K; Ericzon BG; Jonigk D; Janciauskiene S; Nowak G; Ellis ECS
PLoS One; 2017; 12(5):e0177279. PubMed ID: 28486562
[TBL] [Abstract][Full Text] [Related]
6. The role of augmentation therapy in alpha-1 antitrypsin deficiency.
Kueppers F
Curr Med Res Opin; 2011 Mar; 27(3):579-88. PubMed ID: 21226542
[TBL] [Abstract][Full Text] [Related]
7. α1-Antitrypsin activates protein phosphatase 2A to counter lung inflammatory responses.
Geraghty P; Eden E; Pillai M; Campos M; McElvaney NG; Foronjy RF
Am J Respir Crit Care Med; 2014 Dec; 190(11):1229-42. PubMed ID: 25341065
[TBL] [Abstract][Full Text] [Related]
8. Alpha-1-antitrypsin is produced by human neutrophil granulocytes and their precursors and liberated during granule exocytosis.
Clemmensen SN; Jacobsen LC; Rørvig S; Askaa B; Christenson K; Iversen M; Jørgensen MH; Larsen MT; van Deurs B; Ostergaard O; Heegaard NH; Cowland JB; Borregaard N
Eur J Haematol; 2011 Jun; 86(6):517-30. PubMed ID: 21477074
[TBL] [Abstract][Full Text] [Related]
9. How Can We Improve the Detection of Alpha1-Antitrypsin Deficiency?
Ferrarotti I; Poplawska-Wisniewska B; Trevisan MT; Koepke J; Dresel M; Koczulla R; Ottaviani S; Baldo R; Gorrini M; Sala G; Cavallon L; Welte T; Chorostowska-Wynimko J; Luisetti M; Janciauskiene S
PLoS One; 2015; 10(8):e0135316. PubMed ID: 26270547
[TBL] [Abstract][Full Text] [Related]
10. High-level production of wild-type and oxidation-resistant recombinant alpha-1-antitrypsin in glycoengineered CHO cells.
Koyuturk I; Kedia S; Robotham A; Star A; Brochu D; Sauvageau J; Kelly J; Gilbert M; Durocher Y
Biotechnol Bioeng; 2022 Sep; 119(9):2331-2344. PubMed ID: 35508753
[TBL] [Abstract][Full Text] [Related]
11. Alpha-1-antitrypsin aerosolised augmentation abrogates neutrophil elastase-induced expression of cathepsin B and matrix metalloprotease 2 in vivo and in vitro.
Geraghty P; Rogan MP; Greene CM; Brantly ML; O'Neill SJ; Taggart CC; McElvaney NG
Thorax; 2008 Jul; 63(7):621-6. PubMed ID: 18250185
[TBL] [Abstract][Full Text] [Related]
12. alpha-1-Antitrypsin ameliorates cigarette smoke-induced emphysema in the mouse.
Churg A; Wang RD; Xie C; Wright JL
Am J Respir Crit Care Med; 2003 Jul; 168(2):199-207. PubMed ID: 12689849
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study.
Stocks JM; Brantly ML; Wang-Smith L; Campos MA; Chapman KR; Kueppers F; Sandhaus RA; Strange C; Turino G
BMC Clin Pharmacol; 2010 Sep; 10():13. PubMed ID: 20920295
[TBL] [Abstract][Full Text] [Related]
14. Prolastin, a pharmaceutical preparation of purified human alpha1-antitrypsin, blocks endotoxin-mediated cytokine release.
Nita I; Hollander C; Westin U; Janciauskiene SM
Respir Res; 2005 Jan; 6(1):12. PubMed ID: 15683545
[TBL] [Abstract][Full Text] [Related]
15. Z alpha1-antitrypsin polymerizes in the lung and acts as a neutrophil chemoattractant.
Mulgrew AT; Taggart CC; Lawless MW; Greene CM; Brantly ML; O'Neill SJ; McElvaney NG
Chest; 2004 May; 125(5):1952-7. PubMed ID: 15136414
[TBL] [Abstract][Full Text] [Related]
16. [Lack of effect of substitution therapy of alpha1-antitrypsin deficiency].
Dahl R; Hilberg O; Løkke A; Pedersen L; Ringbæk T; Titlestad I
Ugeskr Laeger; 2011 Oct; 173(42):2645-7. PubMed ID: 22027165
[TBL] [Abstract][Full Text] [Related]
17. Alpha-1-antitrypsin augmentation therapy for alpha-1-antitrypsin deficiency.
Hubbard RC; Crystal RG
Am J Med; 1988 Jun; 84(6A):52-62. PubMed ID: 3289387
[TBL] [Abstract][Full Text] [Related]
18. Well-Known and Less Well-Known Functions of Alpha-1 Antitrypsin. Its Role in Chronic Obstructive Pulmonary Disease and Other Disease Developments.
Janciauskiene S; Welte T
Ann Am Thorac Soc; 2016 Aug; 13 Suppl 4():S280-8. PubMed ID: 27564662
[TBL] [Abstract][Full Text] [Related]
19. Comment: comparisons of Aralast and Prolastin, alpha1-protease inhibitors for treatment of alpha1-antitrypsin deficiency.
Petteway SR
Ann Pharmacother; 2006 Feb; 40(2):353-4; author reply 354. PubMed ID: 16449545
[No Abstract] [Full Text] [Related]
20. Biochemical efficacy and safety of a new pooled human plasma alpha(1)-antitrypsin, Respitin.
Stoller JK; Rouhani F; Brantly M; Shahin S; Dweik RA; Stocks JM; Clausen J; Campbell E; Norton F
Chest; 2002 Jul; 122(1):66-74. PubMed ID: 12114340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
